Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy. - Inserm - Institut national de la santé et de la recherche médicale Accéder directement au contenu
Article Dans Une Revue Clinical Journal of the American Society of Nephrology Année : 2006

Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy.

Résumé

Light-, light- and heavy-, and heavy-chain deposition diseases belong to a family of diseases that include light-chain (AL)-amyloid, nonamyloid fibrillary and immunotactoid glomerulonephritis, and cryoglobulinemic glomerulonephritis, in which monoclonal Ig or their subunits become deposited in kidney. In clinical and pathologic terms, light-, light- and heavy-, and heavy-chain deposition diseases essentially are similar and are characterized by prominent renal involvement with severe renal failure; extrarenal manifestations; diabetes-like nodular glomerulosclerosis; marked thickening of tubular basement membranes; and monotypic deposits of light chain, mostly kappa, and/or heavy chain that feature a nonorganized granular, electron-dense appearance by electron microscopy. The most common cause is myeloma. Recent progress has been made in the understanding of the molecular pathomechanisms of Ig-chain deposition and extracellular matrix accumulation, which opens up new therapeutic avenues in addition to eradication of the Ig-secreting plasma cell clone. Because these diseases represent a model of glomerular and interstitial fibrosis that is induced by a single molecule species, a better understanding of their pathomechanisms may help to unravel the pathophysiology of kidney fibrosis and renal disease progression.
Fichier sous embargo
Fichier sous embargo
Date de visibilité indéterminée

Dates et versions

inserm-00169567 , version 1 (04-09-2007)

Identifiants

Citer

Pierre Ronco, Plaisier Emmanuelle, Mougenot Béatrice, Aucouturier Pierre. Immunoglobulin light (heavy)-chain deposition disease: from molecular medicine to pathophysiology-driven therapy.: Light-chain deposition disease. Clinical Journal of the American Society of Nephrology, 2006, 1 (6), pp.1342-50. ⟨10.2215/CJN.01730506⟩. ⟨inserm-00169567⟩
36 Consultations
1 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More